Sutro Biopharma (STRO) Common Equity (2017 - 2025)
Historic Common Equity for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to -$87.3 million.
- Sutro Biopharma's Common Equity fell 17846.43% to -$87.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$87.3 million, marking a year-over-year decrease of 17846.43%. This contributed to the annual value of $44.6 million for FY2024, which is 7019.63% down from last year.
- Latest data reveals that Sutro Biopharma reported Common Equity of -$87.3 million as of Q3 2025, which was down 17846.43% from -$32.1 million recorded in Q2 2025.
- Sutro Biopharma's 5-year Common Equity high stood at $307.5 million for Q2 2021, and its period low was -$87.3 million during Q3 2025.
- In the last 5 years, Sutro Biopharma's Common Equity had a median value of $154.7 million in 2023 and averaged $152.1 million.
- Per our database at Business Quant, Sutro Biopharma's Common Equity soared by 27441.43% in 2021 and then plummeted by 17846.43% in 2025.
- Sutro Biopharma's Common Equity (Quarter) stood at $252.6 million in 2021, then decreased by 14.06% to $217.0 million in 2022, then tumbled by 31.05% to $149.6 million in 2023, then tumbled by 70.2% to $44.6 million in 2024, then crashed by 295.66% to -$87.3 million in 2025.
- Its last three reported values are -$87.3 million in Q3 2025, -$32.1 million for Q2 2025, and -$25.8 million during Q1 2025.